Sirtex exceeds expectations with FY2013 profit
Sirtex Medical (ASX: SRX) has come in ahead of analysts’ expectations this financial year, reporting a total revenue of $100.3 million, an increase of 16% on the previous financial year.
The company reported a net profit after tax of $18.3 million, up 7% on last year, with cash holdings of $52 million at the end of the year compared to $49 million in FY2012.
Sirtex has been one of the best-performing stocks on the ASX during the last financial year, with its share price doubling from around $6 to $12.
This rise is thanks to strong dose sales of Sirtex’s SIR-Spheres, a targeted radioactive liver cancer treatment.
The largest growth was in the US, where sales rose by 21.4%. Across Europe, the Middle East and Africa (EMEA), sales were up 9% and in the Asia-Pacific doses increased by 29.5%.
With work on a new manufacturing facility in Germany progressing to schedule, sales in Europe should continue to grow.
Sirtex has also invested $15.8 million into its global clinical program, which aims to make its targeted radiation therapy a first-line treatment option for patients with liver cancer.
Sirtex shares were trading just under $13 at $12.96 at around 10 am on Friday.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
